Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Basel, September 01, 2021 — Novartis has reached a commercial agreement with the NHS in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address elevated LDL-C in eligible patients with ASCVD across England.

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)

Basel, August 30, 2021 — Novartis will present new data from its robust portfolio and pipeline of advanced therapeutic platforms in solid tumors, with more than 55 abstracts from Novartis-sponsored and investigator-initiated trials accepted at the upcoming European Society for Medical Oncology (ESMO) Congress 2021. The ESMO Congress will be held virtually September 16-21, 2021.

Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO

The FDA has accepted for review Novartis AG's (NYSE: NVS) marketing application seeking approval for asciminib (ABL001) in chronic myeloid leukemia (CML). Under Priority Review, the application is based on data from the Phase 3 ASCEMBL trial, where asciminib was compared to Bosulif (bosutinib) in patients with Philadelphia chromosome-positive CML in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Novartis' STAMP Inhibitor Under FDA Review For Myeloid Leukemia

Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.

Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study

Novartis AG's (NYSE: NVS) Kymriah (tisagenlecleucel) CAR-T therapy failed to meet its primary endpoint of event-free survival in a Phase 3 study in aggressive B-cell non-Hodgkin lymphoma (NHL). The BELINDA study included patients after relapse or lack of response to first-line treatment.

Novartis's Kymriah Flunks In Late-Stage NHL Study

Basel, August 24, 2021 — Novartis today announced an update on the Phase III BELINDA study investigating Kymriah® (tisagenlecleucel) in aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment. The BELINDA study did not meet its primary endpoint of event-free survival compared to treatment with the standard-of-care (SOC). SOC was salvage chemotherapy followed in responding patients by high-dose chemotherapy and stem cell transplant. The safety profile was consistent with the established safety profile of Kymriah. Novartis will complete a full evaluation of the BELINDA data and work with investigators on the future presentation of the results.

Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma

Novartis AG (NYSE: NVS) has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept) 2 mg in patients with diabetic macular edema (DME). Two-year (week 100) data of the KITE study showed consistent results as one year of greater reductions versus aflibercept in central subfield thickness (CSFT), a number of eyes with retinal fluid (a biomarker of the disease), and maintenance of best-corrected visual acuity (BCVA).

Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies

Novartis is a Swiss pharmaceutical giant that's demonstrated strong growth in recent years. It has solid profitability compared to peers, and has a robust pipeline of drugs.

3 Reasons Novartis May Be Your Ticket To A Rich Retirement

AbbVie

Eli Lilly

Merck

Novo Nordisk

Pfizer

Roche Holding AG

The Wall Street firm put big drugmakers' R&D programs through five different tests.

Here Are the Winners of Cowen's Big Pharma R&D Showdown

Illumina

Johnson & Johnson

Moderna

Regeneron Pharmaceuticals

Zoetis

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

Ad hoc announcement pursuant to Art. 53 LR

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA

Ionis Pharma

CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization,  continues to advance in the clinic as the potential first-in-class treatment for lipoprotein(a) or Lp(a)-driven cardiovascular disease.

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

The FDA has granted Orphan Drug Designation to Novartis AG's (NYSE: NVS) NIS793 in combination with standard of care chemotherapy to treat pancreatic cancer. NIS793 is a fully human anti-TGF-β IgG2 monoclonal antibody designed to inhibit the TGF-β pathway in tumor cells and modulate the tumor microenvironment.

Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer

Novartis AG ( NVS , Financial) is ahead of the pack of pharma companies developing a new type of cancer treatment that could evolve into a $10 billion market, reported the California News Times.

Novartis Leading in $10 Billion Market for New Cancer Treatment

Novartis CEO Vasant Narasimhan told CNBC there are now lower rates of diagnoses due to reduced hospital visits during the coronavirus pandemic.

Novartis CEO says Covid-related doctor visit delays likely impacting cancer diagnosis rates

Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.

Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers

Ashtead Group PLC

British American Tobacco

Diageo

EssilorLuxottica SA

Fresenius Medical Care

L'Oreal SA

Nestle SA

Sanofi

Unilever

Wolters Kluwer NV

Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your Portfolio appeared first on InvestorPlace.

15 European Dividend Aristocrats to Diversify Your Portfolio

Novartis AG (NVS) CEO Vas Narasimhan on Q2 2021 Results - Earnings Call Transcript

Novartis AG (NYSE: NVS) boosted its second-quarter core net income by 20% Y/Y to $3.7 billion, beating market expectations as it kept its 2021 guidance. Earnings: The Company posted core EPS of $1.66, well ahead of the consensus of $1.52.

Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance

ZURICH (Reuters) -Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.

Novartis posts Q2 profit beat, keeps 2021 guidance

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the root causes of systemic disparities in health outcomes and create greater diversity, equity and inclusion across the research and development ecosystem.

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Among members of Big Pharma, Novartis AG ( NVS , Financial) brought the most novel medicines to market in the past five years, according to a report from Evaluate Vantage.

Novartis, Eli Lilly and AbbVie Top 5-Year New Drug Productivity List

Biogen

uniQure

SAGE Therapeutics

Several drugmakers have important clinical trial updates on the way.

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis AG (NYSE: NVS) at the Credit Suisse ESG Forum Switzerland virtual event.  Ensovibep is currently being studied in Phase 2 single-arm pilot study in ambulatory patients in the Netherlands; a global Phase 2/3 study in ambulatory patients, in collaboration with Novartis (EMPATHY); and a National Institutes of Health-sponsored global Phase 3 study in hospitalized patients as part of the ACTIV-3 master protocol.

Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant

News for Novartis Stock (NVS)